

Noucor Completes Acquisition of HELM Pharmaceuticals

Transformational acquisition creates a stronger European pharmaceutical platform with enhanced capabilities, broader international reach and significant opportunities for future growth

Barcelona, Spain and Hamburg, Germany, 5th of October 2026

Noucor today announced the successful completion of the acquisition of HELM Pharmaceuticals.

The transaction marks a major milestone in Noucor's evolution as an international pharmaceutical group and significantly strengthens the company's position across product development, regulatory affairs, supply chain management, commercial operations and lifecycle management.

Helm Pharmaceuticals brings a high-quality portfolio of finished dosage form products, strong market positions across multiple therapeutic categories, a proven operating platform and a highly experienced team. The combination creates a stronger organization with expanded capabilities to serve patients, healthcare professionals and partners across Europe and international markets. **Following the acquisition, Noucor is expected to reach approximately €200 million in revenue by the end of 2026.**

"This is a landmark moment for Noucor," said **David Perdigó, Chief Executive Officer of Noucor Group**. *"We are delighted to welcome the HELM's team. Together we are creating a stronger pharmaceutical platform with greater scale, broader expertise and enhanced capabilities to drive future growth. The combination brings together complementary strengths, shared values and a common commitment to quality, innovation and customer service. We look forward to building on the strong foundations established by both organizations and creating new opportunities for our employees, customers and partners"*, Perdigó highlighted.

Dr. Annette Eschler, Managing Director of HELM Pharmaceuticals, commented:

"HELM Pharmaceuticals has built a strong foundation and delivered excellent operational performance. We are confident that Noucor is the right long-term owner to support the continued growth and development of the business, its employees and its partners."

The acquisition supports Noucor's long-term strategy to accelerate growth through a combination of organic expansion, portfolio development and selective strategic acquisitions. The company, **which will continue to be headquartered in Barcelona**, expects the combination to enhance its development pipeline, strengthen international market access, broaden commercial capabilities and create additional opportunities for operational excellence.

Noucor intends to ensure a seamless integration process, maintaining business continuity for customers, suppliers and partners while preserving the entrepreneurial culture and expertise that have contributed to the success of both organizations.

Employees from both companies will play a key role in shaping the future of the combined business. Noucor believes the acquisition creates an attractive platform for professional development, innovation and sustainable long-term growth.

"The completion of this transaction is not the end of a process; it is the beginning of an exciting new chapter," added David Perdigó. "Our ambition is clear: to build one of Europe's most respected pharmaceutical platforms, combining scientific excellence, operational discipline and a relentless focus on patients and customers."

Société Générale and PwC acted as financial advisors to Noucor and Garrigues and Gleiss Lutz served as legal counsel

Jefferies acted as financial advisor to Helm and Freshfields served as legal counsel

About Noucor

Noucor is an international healthcare group, backed by MCH Private Equity and a group of local family offices which is dedicated to the development, manufacturing and commercialization of pharmaceutical products. Headquartered in Barcelona, the company operates across multiple international markets and is committed to improving people's lives through high-quality healthcare solutions. Learn more: www.noucor.com

About Helm Pharmaceuticals

Helm Pharmaceuticals has been developing finished dosage form products for 30 years, gaining substantial knowledge in this field. Customers get access to more than 40 molecules in various therapeutical areas with different dosage forms and to more than 30 ongoing development projects in different development stages and around 40 projects in early feasibility phase. Helm Pharmaceuticals and its customers hold more than 1,000 active marketing authorization across the world, with significant commercial activities in Europe and the US. Learn more: www.helmpharma.com

The HELM group is a global, family-owned chemical distribution and marketing company headquartered in Hamburg, Germany, with operations in more than 30 countries. Focus areas are chemicals, crop solutions and specialty & advanced materials.